secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001104659-25-082783
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared
--------------------------------------------------------------------------------

- 66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
- No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).
- Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.
- HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.
- Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/0001104659-25-082783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/tm2524197d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-082783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer